- Full Report (334k PDF)
- 2-Page summary (93k PDF)
- Descargar El Resumen De 2 Páginas (408k PDF)
- Download Adobe Acrobat Reader
The spasming, sore muscles that can be the culprit behind back and neck aches and other conditions can leave many people reaching for a strong medicine to ease their pain, as evidenced by the more than $1 billion in U.S. sales potent muscle relaxant drugs racked up last year. But our latest Best Buy Drug report recommends that your best first option for relief from these conditions is a common over-the-counter pain reliever, such as acetaminophen (Tylenol and generics), aspirin, ibuprofen (Advil and generics), or naproxen (Aleve and generics). The muscle relaxants are no better than these nonprescription pain relievers and they carry dangerous side effects, such as addiction and sedation.
Where muscle relaxants could be a good first option is the treatment of muscle spasticity associated with disorders such as cerebral palsy, multiple sclerosis or stroke. Due to the seriousness of these conditions, the benefits of the drugs may be worth the potential risks and consequently, the medicines are considered first line therapy for spasticity triggered by these disorders.
The sections below give our Best Buy recommendations for each condition.
Muscle spasticity
Damage to the brain or spinal cord from diseases such as cerebral palsy and multiple sclerosis can interfere with normal muscle relaxation and result in involuntary muscle contractions that can be very painful and impair your ability to walk, sleep, work or just function normally. Severe cases can result in profound disability, including an inability to straighten out joints. Three of the nine available muscle relaxants are FDA approved for treating spasticity.
Taking into consideration all of the evidence on muscle relaxants for spasticity, our Best Buy pick is:
- Generic baclofen tablet
Baclofen costs between $27 and $60 for a 30-day supply, so you could save a significant amount of money over some of the more expensive brand-name muscle relaxants, which can cost from $200 to up to $486 a month.
Muscle spasms
Muscle spasms, on the other hand, are associated with much more common conditions that affect the muscles, bones and associated tissues, including headaches, back and neck aches, and fibromyalgia. The spasms can be very painful and reduce your ability to function. If you have muscle spasms due to one of these conditions that have not responded to nondrug therapies, then over-the-counter pain relievers--acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen or naproxen-- are a reasonable first option. But if these don't work or you can't tolerate acetaminophen or NSAIDs because of liver problems, bleeding ulcers or heart issues, then you may want to consider trying a muscle relaxant.
If you and your doctor have decided to try a muscle relaxant to treat muscle spasms, taking all of the evidence into consideration, we chose the following as a Best Buy:
- Generic cyclobenzaprine tablet
Cyclobenzaprine is supported by the strongest body of evidence. Also, it is available in a generic form that costs $8 to $15 for a seven-day course, which makes it one of the least expensive generic muscle relaxants and significantly less costly than brand-name ones that can run more than $100.
We recommend avoiding carisoprodol (Soma) because it is associated with a high risk of abuse and addiction potential not seen with other skeletal muscle relaxants. Despite these risks, it is a widely used medicine and one of the top-selling muscle relaxants, racking up $204 million in sales of the generic drug last year, according to SDI/Verispan.
In addition to sedation, the most common side effects associated with muscle relaxants include weakness or fatigue, dizziness, and dry mouth.
Last updated December 20092. Prices reflect the nationwide retail average for August 2009, rounded to the nearest dollar. Information is derived by Consumer Reports Best Buy Drugs from data provided by Wolters Kluwer Health, Pharmaceutical Audit Suite®. Wolters Kluwer Health is not involved in our analysis or recommendations.
- Full Report (334k PDF)
- 2-Page summary (93k PDF)











